Visterra Withdrawn, Nasdaq: VIST

Developing vaccines for influenza A, Dengue, Zika and multiple myeloma.

Industry: Health Care

Latest Trade: ()

First Day Return:

Return from IPO:

Industry: Health Care

We are a clinical-stage biopharmaceutical company focused on applying our novel Hierotope® platform to identify unique disease targets and to design and engineer precision antibody-based biological medicines for infectious and non-infectious diseases. We believe that our platform enables us to address the significant unmet need for effective therapies to prevent and treat infectious diseases caused by organisms that have a high degree of diversity among strains, frequent mutations and a high prevalence of treatment resistance. Our platform also enables us to design and engineer antibody-based biological product candidates for the treatment of non-infectious diseases that are not being adequately addressed with conventional treatment approaches. We believe our platform will enable the advancement of one product candidate each year to be ready for submission of an investigational new drug application, or IND.
more less
IPO News for Visterra
more
IPO Data
IPO File Date 01/05/2016
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 3.9
Deal Size ($mm) $50
IPO Data
IPO Date
Offer Price
Price Range $12.00 - $14.00
Offer Shares (mm) 3.9
Deal Size ($mm) $50
Underwriters
more
Company Data
Headquarters Cambridge, MA
Founded 2007
Employees 42
Website www.visterrainc.com